Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Explore practical methods to assign budgeting tasks fairly, prevent bottlenecks, and foster teamwork in money management.
18,314 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
MISMO and ALTA unveiled two datasets in candidate recommendation status to digitize ALTA title and settlement data, s...
New York’s 2025 bonuses hit an all-time high, with payouts topping $49.2 billion and the average near $247k. Yet the ...
UBS cuts Mosaic’s price target to $27, citing squeezed phosphate margins from higher sulfur and input costs, as Wall ...
After a stunning quarterly update, Micron stock tumbled on fears about memory cycles. This guide breaks down why the ...
Netflix unveiled a broad price increase across every U.S. tier, with an 11% average lift. JPMorgan says the move coul...
Rumors swirl about SpaceX planning an IPO at a staggering $1.75 trillion. This article breaks down what that would me...
U.S. consumer discretionary stocks rise as demand improves in March 2026. Analysts cite pricing power and resilient c...
TD Cowen boosts its Match Group target on better Tinder metrics, while UBS stays cautious. The market tests whether T...
As the nation nears its Semiquincentennial, a bold campaign seeks to make July 4, 2026 the largest day of charitable ...
This guide breaks down what Greenlight Re (GLRE) investors should watch in the first-quarter 2026 results. Learn how ...
As AI accelerates efficiency, middle managers face restructuring across industries. Investors are weighing earnings i...